NO20061110L - Polymorfe former av rifaximin, fremgangsmater for deres fremstilling og anvendelse derav i medisinske preparater - Google Patents

Polymorfe former av rifaximin, fremgangsmater for deres fremstilling og anvendelse derav i medisinske preparater

Info

Publication number
NO20061110L
NO20061110L NO20061110A NO20061110A NO20061110L NO 20061110 L NO20061110 L NO 20061110L NO 20061110 A NO20061110 A NO 20061110A NO 20061110 A NO20061110 A NO 20061110A NO 20061110 L NO20061110 L NO 20061110L
Authority
NO
Norway
Prior art keywords
rifaximin
preparation
polymorphic forms
methods
medical preparations
Prior art date
Application number
NO20061110A
Other languages
English (en)
Other versions
NO334950B1 (no
Inventor
Manuela Campana
Giuseppe C Viscomi
Goffredo Rosini
Dario Braga
Donatella Confortini
Vincenzo Cannata
Paolo Righi
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061110(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of NO20061110L publication Critical patent/NO20061110L/no
Publication of NO334950B1 publication Critical patent/NO334950B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Electromagnetism (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formålet ved oppfinnelsen er krystallinske polymorfe former av rifaximin (INN), henvist til som rifaximin ? og rifaximin ?, og en dårlig krystallinsk form henvist til som rifaximin ?, nyttig i fremstillingen av medikamenter inneholdende rifaximin for den orale og topiske anvendelsen og oppnådd ved hjelp av en krystalliseringsprosess utført ved a varmeoppløse rårifaximinet i etylalkohol og forårsake krystalliseringen av produktet ved å tilsette vann med en forhåndsgitt temperatur og i en forhåndsgitt tidsperiode, etterfulgt av tørking under kontrollerte betingelser inntil oppnåelse av et nøyaktig vanninnhold i sluttproduktet.
NO20061110A 2003-11-07 2006-03-08 Polymorfe former av rifaximin, fremgangsmåter for deres fremstilling og anvendelse derav i medisinske preparater NO334950B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e
PCT/EP2004/012490 WO2005044823A2 (en) 2003-11-07 2004-11-04 Polymorphous forms of rifaximin as antibiotics

Publications (2)

Publication Number Publication Date
NO20061110L true NO20061110L (no) 2006-04-19
NO334950B1 NO334950B1 (no) 2014-08-04

Family

ID=33187382

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061110A NO334950B1 (no) 2003-11-07 2006-03-08 Polymorfe former av rifaximin, fremgangsmåter for deres fremstilling og anvendelse derav i medisinske preparater

Country Status (38)

Country Link
US (5) US7045620B2 (no)
EP (6) EP1557421B1 (no)
JP (5) JP2005139161A (no)
KR (4) KR20050043589A (no)
CN (4) CN1613858A (no)
AR (3) AR043547A1 (no)
AT (3) ATE421965T1 (no)
AU (2) AU2004200964A1 (no)
BR (2) BRPI0402382A (no)
CA (2) CA2460384A1 (no)
CL (1) CL2004000498A1 (no)
CO (1) CO5560083A1 (no)
CY (3) CY1108017T1 (no)
DE (4) DE602004006367C5 (no)
DK (3) DK1676848T3 (no)
ES (3) ES2320160T4 (no)
HK (3) HK1092151A1 (no)
HR (2) HRP20040265A2 (no)
IL (2) IL160798A0 (no)
IT (1) ITMI20032144A1 (no)
JO (1) JO2470B1 (no)
MA (1) MA27069A1 (no)
MD (1) MD3653G8 (no)
ME (1) ME00424B (no)
MX (2) MXPA04002353A (no)
NO (1) NO334950B1 (no)
NZ (1) NZ531622A (no)
PL (3) PL1676847T3 (no)
PT (3) PT1557421E (no)
RS (4) RS54568B1 (no)
RU (1) RU2270200C2 (no)
SI (3) SI1676848T1 (no)
TN (2) TNSN04044A1 (no)
TW (1) TWI285107B (no)
UA (1) UA86384C2 (no)
WO (1) WO2005044823A2 (no)
YU (1) YU24804A (no)
ZA (1) ZA200401948B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20074988L (no) * 2005-03-03 2007-11-30 Alfa Wassermann Spa Nye polymorfe former av rifaximin, prosesser for deres fremstilling og anvendelse derav i medisin

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0714724A8 (pt) 2006-08-02 2018-04-10 Salix Pharmaceuticals Inc métodos para tratar enterite, para proteger contra a enterite, contra a lesão à mucosa do cólon e contra a inflamação colorretal induzidas pela radiação, para tratar enterite em um indivíduo ou monitorar o progresso de um indivíduo que é tratado de enterite, para selecionar um indivíduo para o tratamento de enterite, e, para tratar diarréia profilaticamente.
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
NZ575550A (en) * 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
DK2011486T3 (da) * 2007-07-06 2012-09-03 Lupin Ltd Farmaceutiske sammensætninger af rifaximin
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
EA021176B1 (ru) * 2008-02-25 2015-04-30 Сэликс Фармасьютиклз, Лтд. Полиморфная форма рифаксимина и её применение
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
RU2519649C2 (ru) * 2008-02-26 2014-06-20 Саликс Фармасьютикалз, Лтд. Способы лечения заболеваний кишечника
SI2294012T1 (sl) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
US8980872B2 (en) 2008-09-26 2015-03-17 Aska Pharmaceutical Co., Ltd. Agent for preventing and/or treating functional gastrointestinal disorder
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2010040020A1 (en) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
BRPI1010028A2 (pt) 2009-06-02 2019-02-12 Salix Pharmaceuticals, Ltd. métodos de tratamento de encefalopatia hepática
JP2013504597A (ja) 2009-09-13 2013-02-07 サリックス ファーマスーティカルズ，リミテッド 過敏性腸症候群（ｉｂｓ）の治療方法
PE20121185A1 (es) * 2009-10-27 2012-09-15 Lupin Ltd Dispersion solida de rifaximina
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
CA2781580A1 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
US8952159B2 (en) † 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN103269587A (zh) * 2010-06-03 2013-08-28 萨利克斯药品有限公司 利福昔明的新形式及其用途
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
MY165086A (en) * 2010-07-12 2018-02-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
CN103827122B (zh) 2011-02-11 2016-08-31 萨利克斯药品有限公司 利福昔明的形式及其用途
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2854380A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
AU2014229467A1 (en) 2013-03-15 2015-08-06 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections.
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
EP2983647B1 (en) 2013-04-12 2020-09-09 Alfasigma S.p.A. Nsaid administration and related compositions, methods and systems
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3134415A4 (en) 2014-04-19 2017-10-25 Granules India Limited An improved process for the preparation of rifamycin derivatives
WO2015171493A1 (en) 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
JP6576953B2 (ja) 2014-05-12 2019-09-18 アルファシグマ ソシエタ ペル アチオニ リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
MX2016016458A (es) * 2014-06-30 2017-07-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
EP3434265B1 (en) 2016-03-24 2021-07-07 Sandoz AG Pharmaceutical composition containing rifaximin alpha & delta
EP3536311B1 (en) 2016-03-24 2021-12-22 Sandoz AG Storage stable composition comprising rifaximin alpha
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
WO2018197538A1 (en) 2017-04-26 2018-11-01 Sandoz Ag Oral dosage form comprising rifaximin in form beta
DK3645539T3 (da) 2017-06-26 2021-05-10 Biofer Spa Pyrido-imidazo-rifamycin-derivater som antibakterielt middel
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
EP4034091A1 (en) 2019-09-24 2022-08-03 Bausch Health Ireland Limited Rifaximin liquid formulations
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
DE69111607T2 (de) * 1990-06-29 1995-12-21 Lepetit Spa Reine kristalline form von rifapentin.
US20020048610A1 (en) * 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
JP4180368B2 (ja) * 2000-10-31 2008-11-12 サンド・アクチエンゲゼルシヤフト 塩酸ベンラファキシンの結晶形
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
NZ575550A (en) 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
DK2011486T3 (da) 2007-07-06 2012-09-03 Lupin Ltd Farmaceutiske sammensætninger af rifaximin
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
EA021176B1 (ru) 2008-02-25 2015-04-30 Сэликс Фармасьютиклз, Лтд. Полиморфная форма рифаксимина и её применение

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20074988L (no) * 2005-03-03 2007-11-30 Alfa Wassermann Spa Nye polymorfe former av rifaximin, prosesser for deres fremstilling og anvendelse derav i medisin
NO342197B1 (no) * 2005-03-03 2018-04-16 Alfasigma Spa Nye polymorfe former av rifaximin, prosesser for deres fremstilling og anvendelse derav i medisin

Also Published As

Publication number Publication date
DK1676847T3 (da) 2009-05-11
PT1676847E (pt) 2009-04-09
RS20060168A (en) 2008-09-29
ES2244364T1 (es) 2005-12-16
UA86384C2 (uk) 2009-04-27
ATE421965T1 (de) 2009-02-15
RS54569B1 (en) 2016-06-30
IL174271A (en) 2010-12-30
CN101260115B (zh) 2011-11-23
TW200515913A (en) 2005-05-16
CY1108964T1 (el) 2014-07-02
MXPA06002644A (es) 2006-06-06
US20080132530A1 (en) 2008-06-05
KR100855084B1 (ko) 2008-08-29
DK1676848T3 (da) 2009-05-11
MA27069A1 (fr) 2004-12-20
CY1108017T1 (el) 2013-09-04
JP2007509904A (ja) 2007-04-19
IL160798A0 (en) 2004-08-31
ES2244364T3 (es) 2007-12-01
RU2004108953A (ru) 2005-10-27
US8173801B2 (en) 2012-05-08
PL1557421T3 (pl) 2007-08-31
MXPA04002353A (es) 2005-05-11
CN101260114B (zh) 2012-11-28
HK1092151A1 (en) 2007-02-02
MD20060080A (en) 2006-11-30
US20050101598A1 (en) 2005-05-12
RS20150292A1 (en) 2015-10-30
CY1108909T1 (el) 2014-07-02
DE04005541T1 (de) 2005-12-29
ZA200401948B (en) 2004-04-29
DE602004006367C5 (de) 2019-04-04
AU2004287601A1 (en) 2005-05-19
YU24804A (sh) 2006-08-17
CN101260115A (zh) 2008-09-10
IL174271A0 (en) 2006-08-01
MD3653F2 (en) 2008-07-31
EP1676848A1 (en) 2006-07-05
BRPI0407149A8 (pt) 2019-01-15
ME00424B (me) 2011-10-10
TWI285107B (en) 2007-08-11
KR20060110737A (ko) 2006-10-25
US20120059023A1 (en) 2012-03-08
SI1557421T1 (sl) 2007-08-31
SI1676847T1 (sl) 2009-06-30
ATE361927T1 (de) 2007-06-15
BRPI0407149A (pt) 2006-02-07
TNSN04044A1 (en) 2006-06-01
CN1613858A (zh) 2005-05-11
KR20070113327A (ko) 2007-11-28
CN101260114A (zh) 2008-09-10
ES2320161T3 (es) 2009-05-19
KR20070113326A (ko) 2007-11-28
CN1886408A (zh) 2006-12-27
AU2004287601B8 (en) 2009-03-05
CA2460384A1 (en) 2005-05-07
JO2470B1 (en) 2009-01-20
CA2538546A1 (en) 2005-05-19
NO334950B1 (no) 2014-08-04
RS54571B1 (en) 2016-06-30
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
RS54568B1 (en) 2016-06-30
JP2005139161A (ja) 2005-06-02
HK1073657A1 (en) 2005-10-14
DE602004019298D1 (de) 2009-03-19
HRP20060093A2 (en) 2006-05-31
EP1676847A1 (en) 2006-07-05
RS20150291A1 (en) 2015-10-30
HRP20060093B1 (hr) 2015-12-18
CO5560083A1 (es) 2005-09-30
ATE421966T1 (de) 2009-02-15
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
WO2005044823A2 (en) 2005-05-19
JP2014177500A (ja) 2014-09-25
AU2004200964A1 (en) 2005-05-26
SI1676848T1 (sl) 2009-06-30
EP1557421A1 (en) 2005-07-27
DK1557421T3 (da) 2007-09-17
DE602004006367T2 (de) 2007-09-06
US7915275B2 (en) 2011-03-29
KR100867751B1 (ko) 2008-11-10
JP2011046738A (ja) 2011-03-10
ES2320160T4 (es) 2011-03-09
PL1676847T3 (pl) 2009-07-31
MD3653G8 (ro) 2016-08-31
EP2210893A1 (en) 2010-07-28
US7045620B2 (en) 2006-05-16
AR081992A2 (es) 2012-10-31
EP1676847B1 (en) 2009-01-28
US8404704B2 (en) 2013-03-26
US20110160449A1 (en) 2011-06-30
EP1676848B1 (en) 2009-01-28
PT1557421E (pt) 2007-07-31
RU2270200C2 (ru) 2006-02-20
EP1557421B1 (en) 2007-05-09
US20050272754A1 (en) 2005-12-08
KR20050043589A (ko) 2005-05-11
JP5199576B2 (ja) 2013-05-15
DE602004006367D1 (de) 2007-06-21
AU2004287601B2 (en) 2009-02-26
CA2538546C (en) 2011-04-19
AR043547A1 (es) 2005-08-03
ITMI20032144A1 (it) 2005-05-08
CN1886408B (zh) 2010-06-09
AR081991A2 (es) 2012-10-31
JP5635376B2 (ja) 2014-12-03
KR100883216B1 (ko) 2009-02-13
HK1092150A1 (en) 2007-02-02
JP2011057698A (ja) 2011-03-24
CL2004000498A1 (es) 2005-03-11
TNSN06069A1 (en) 2007-10-03
BRPI0402382A (pt) 2005-06-28
PT1676848E (pt) 2009-04-09
NZ531622A (en) 2004-10-29
EP1682556A2 (en) 2006-07-26
DE602004019296D1 (de) 2009-03-19

Similar Documents

Publication Publication Date Title
NO20061110L (no) Polymorfe former av rifaximin, fremgangsmater for deres fremstilling og anvendelse derav i medisinske preparater
NO20074988L (no) Nye polymorfe former av rifaximin, prosesser for deres fremstilling og anvendelse derav i medisin
NO20053748L (no) Pyrrolopyridazinderivater.
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
WO2006078621A3 (en) 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
NO20066055L (no) Pyridinderivater
NO20052805L (no) Substituerte pyrrolo-pyrazolderivater som kinase-inhibitorer
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
NO20074781L (no) 4-Oksokinazolin-3-ylbenzamidderivater for behandling av cytokinsykdommer
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
NO20081370L (no) Fenyl-[1,2,4]-okadiazol-5-on-derivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
NO20081369L (no) Fenyl- og pyridinyl-1,2,4-oksadiazolonderivater, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
DK1751093T3 (da) Substituerede cyklohexyleddikesyre-derivater
NO20092058L (no) Heteroaryl pyrrolidinyl ketonderivater
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20082054L (no) Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser
NO20072165L (no) Metabolitter av visse (1,4)diazepino(6,7,1-IJ)kinolinderivater og fremgangsmater for fremstilling og anvendelse derav